Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients
ConclusionIn our study, we propose a model able to describe, meanwhile, and its main metabolites, with a complex absorption process and inclusion of enzyme activity covariates such as CDA and UH2/U ratio.Trial registration Eudract 2008-004136-20, 2008/11/26
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Statistics | Study | Toxicology | Xeloda